{"filing":{"accession_number":"0001193125-26-298739","cik":"0001369568","ticker":"CPRX","company_name":"CATALYST PHARMACEUTICALS, INC.","form":"8-K","filing_date":"2026-07-08","report_date":null,"primary_document":"d109692d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1369568/000119312526298739/d109692d8k.htm"},"events":[{"id":17146,"run_id":15348,"accession_number":"0001193125-26-298739","anchor_item_number":"5.02","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Catalyst Pharmaceuticals stockholders approved the anticipated merger with Angelini Pharma at a special meeting held on July 8, 2026, with the Merger Proposal receiving approximately 98.8% of votes cast (97,340,180 votes in favor). Directors' conditional resignations were disclosed in connection with the anticipated consummation of the Merger Agreement dated May 6, 2026, which constitutes a material acquisition and change of control event.","company_name":"CATALYST PHARMACEUTICALS, INC.","ticker":"CPRX","filing_date":"2026-07-08","form":"8-K","submitted_at":null,"items":[{"id":15484,"accession_number":"0001193125-26-298739","item_number":"5.02","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Although Item 5.02 typically covers executive departures and appointments, the substance of this disclosure centers on the anticipated merger with Angelini Pharma and the resulting change of control. The directors' conditional resignations are ancillary to the Merger Agreement dated May 6, 2026, which constitutes a material acquisition and change of control event. The filing explicitly references the previously reported Merger Agreement and frames the director resignations as \"in connection with the anticipated consummation of the Merger,\" making the M\u0026A activity the principal material event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T12:58:26.137355+00:00","company_name":"","ticker":null,"filing_date":""},{"id":15485,"accession_number":"0001193125-26-298739","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 discloses the results of a special stockholder meeting held on July 8, 2026, where Catalyst Pharmaceuticals stockholders voted on three proposals, most critically the Merger Proposal to approve the merger with Angelini Pharma. The Merger Proposal was approved with 97,340,180 votes in favor (approximately 98.8% of votes cast), satisfying a closing condition under the Merger Agreement. This is a material event affecting the registrant's future as it represents shareholder approval of a transformative M\u0026A transaction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T12:58:26.137355+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":15484,"accession_number":"0001193125-26-298739","item_number":"5.02","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Although Item 5.02 typically covers executive departures and appointments, the substance of this disclosure centers on the anticipated merger with Angelini Pharma and the resulting change of control. The directors' conditional resignations are ancillary to the Merger Agreement dated May 6, 2026, which constitutes a material acquisition and change of control event. The filing explicitly references the previously reported Merger Agreement and frames the director resignations as \"in connection with the anticipated consummation of the Merger,\" making the M\u0026A activity the principal material event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T12:58:26.137355+00:00","company_name":"CATALYST PHARMACEUTICALS, INC.","ticker":"CPRX","filing_date":"2026-07-08"},{"id":15485,"accession_number":"0001193125-26-298739","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 discloses the results of a special stockholder meeting held on July 8, 2026, where Catalyst Pharmaceuticals stockholders voted on three proposals, most critically the Merger Proposal to approve the merger with Angelini Pharma. The Merger Proposal was approved with 97,340,180 votes in favor (approximately 98.8% of votes cast), satisfying a closing condition under the Merger Agreement. This is a material event affecting the registrant's future as it represents shareholder approval of a transformative M\u0026A transaction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T12:58:26.137355+00:00","company_name":"CATALYST PHARMACEUTICALS, INC.","ticker":"CPRX","filing_date":"2026-07-08"}]}